<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560481</url>
  </required_header>
  <id_info>
    <org_study_id>NTC00940472</org_study_id>
    <nct_id>NCT01560481</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers</brief_title>
  <acronym>NTC00940472</acronym>
  <official_title>Randomized Clinical Trial to Evaluate Safety, Tolerability and PK-PD Profile of Metformin Glycinate 620 mg,1240 mg, 2480 mg and Metformin Chlorhydrate 1000 mg of One Single Dose, Multiple Dose and After Food Intake.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the
      treatment of type 2 diabetes. Metformin Glycinate was found to improve metabolic control in
      naive patients with type 2 diabetes.

      The objective of this study is to evaluate the safety, tolerability and pK profile of
      Metformin Glycinate 620 mg QD, 1240 mg QD, 2480 mg QD, after administration of one single
      dose, in step A. In step A will be included 25 volunteers.

      In step B the objective is to evaluate Safety, tolerability and pK profile of Metformin
      Glycinate 620 mg BID, after administration of multiple dose during 8 days. In step B will be
      included 24 volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Step A: Number of Adverse Events of Metformin Glycinate 620 mg QD, 1240 mg QD, 2480 mg QD, after administration of one single dose</measure>
    <time_frame>35 days</time_frame>
    <description>Tolerability:
adverse events,
systolic and diastolic blood pressure, pulse rate and temperature
pulse rate and ECG alterations
alterations in haematology, plasma chemistry, and urine analyses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step B: Number of Adverse Events of Metformin Glycinate 620 mg BID, after administration of multiple dose during 8 days</measure>
    <time_frame>25 days</time_frame>
    <description>Tolerability:
adverse events,
systolic and diastolic blood pressure, pulse rate and temperature
pulse rate and ECG alterations
alterations in haematology, plasma chemistry, and urine analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Step A: Bioavailability (AUC) of metformin glycinate 620 mg QD, 1240 mg QD, 2480 mg QD after administration of one single dose with metformin Chlorhydrate 1000 mg QD.</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Linear and dose-proportional (AUC) pharmacokinetic of 620 mg, 1240 mg and 2480 strengths of metformin glycinate</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Bioavailability (AUC) of metformin glycinate 1240 mg QD in fasted subjects and after the intake of fat rich breakfast</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Pharmacokinetic profile (AUC) of metformin glycinate 620mg QD, 1240 mg QD, 2480 mg QD after administration one single dose and pharmacokinetic profile of metformin chlorhydrate 1000mg QD.</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step B: Bioavailability (AUC) of metformin glycinate 620 mg BID and bioavailability of metformin chlorhydrate 500mg BID, after administration of multiple doses during 8 days.</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step B: Pharmacokinetic profile (AUC) of metformin glycinate 620mg BID after administration of multiple doses during 8 days</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Bioavailability (Cmax) of metformin glycinate 620 mg QD, 1240 mg QD, 2480 mg QD after administration of one single dose with metformin Chlorhydrate 1000 mg QD.</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Linear and dose-proportional pharmacokinetic (Cmax) of 620 mg, 1240 mg and 2480 strengths of metformin glycinate</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Bioavailability (Cmax) of metformin glycinate 1240 mg QD in fasted subjects and after the intake of fat rich breakfast</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step A: Pharmacokinetic profile (Cmax) of metformin glycinate 620mg QD, 1240 mg QD, 2480 mg QD after administration one single dose and pharmacokinetic profile of metformin chlorhydrate 1000mg QD.</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step B: Bioavailability (Cmax) of metformin glycinate 620 mg BID and bioavailability of metformin chlorhydrate 500mg BID, after administration of multiple doses during 8 days.</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step B: Pharmacokinetic profile (Cmax) of metformin glycinate 620mg BID after administration of multiple doses during 8 days</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Step A: metformin glycinate 620 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>620mg single dose by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step A: metformin glycinate 1240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1240mg single dose by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step A: metformin glycinate 2480 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2480mg single dose by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step A: metformin hydrochloride 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg single dose by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step A: metformin glycinate 1240 mg, food intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1240mg single dose by mouth after food intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step B: metformin glycinate 620 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>620mg BID for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step B: metformin hydrochloride 500 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg tablets BID for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step A: metformin glycinate 620 mg single dose</intervention_name>
    <description>metformin glycinate 620 mg single dose</description>
    <arm_group_label>Step A: metformin glycinate 620 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step A: metformin glycinate 1240 mg single dose</intervention_name>
    <description>metformin glycinate 1240 mg single dose</description>
    <arm_group_label>Step A: metformin glycinate 1240 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step A: metformin glycinate 2480 mg single dose</intervention_name>
    <description>metformin glycinate 2480 mg single dose</description>
    <arm_group_label>Step A: metformin glycinate 2480 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step A: metformin hydrochloride 1000 mg single dose</intervention_name>
    <description>metformin Chlorhydrate 1000 mg single dose</description>
    <arm_group_label>Step A: metformin hydrochloride 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step A: metformin glycinate 1240 mg,food intake</intervention_name>
    <description>metformin glycinate 1240 mg, intake of food</description>
    <arm_group_label>Step A: metformin glycinate 1240 mg, food intake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step B: metformin glycinate 620 mg BID</intervention_name>
    <description>metformin glycinate 620 mg BID, 8 days</description>
    <arm_group_label>Step B: metformin glycinate 620 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step B: metformin hydrochloride 500 mg BID</intervention_name>
    <description>metformin Chlorhydrate 500 mg BID, 8 days</description>
    <arm_group_label>Step B: metformin hydrochloride 500 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 45 years.

          -  Weight within normal ranges (Quetelet index between 21 and 26) (weight (kg)/height
             (m2).

          -  Adequate physical examination and clinical history

          -  No organic and psychiatric disorder

          -  Normal Blood pressure, Pulse Rate, temperature and ECG.

          -  Lab test within normal values according to reference lab values of Biochemistry lab of
             Hospital Santa Creu I Sant Pau. It will be allowed changes according to clinical
             criteria of the clinical staff of ICIM-SANT PAU

          -  Females of childbearing potential with adequate contraceptive precautions, other than
             oral contraceptives and negative urine pregnancy test.

          -  No participation in any other clinical trial within the previous two months before the
             initiation of this study.

          -  No blood donation within the previous four weeks before the initiation of this study.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Drugs or alcohol abuse.

          -  Consumer of stimulant drinks (&gt; 5 coffees, teas, cola drinks).

          -  Smokers (&gt; 10 cigars).

          -  Precedents of drugs allergy or hypersensitivity

          -  Intake of any other medication within the previous 15 days before this study.

          -  Positive HIV, HBV or HCV.

          -  Chronic disease (cardiovascular, respiratory, endocrine, gastrointestinal,
             hematologic, neurologic or others).

          -  Prior surgery within the previous six months before the initiation of this study.

          -  Pregnant women or breastfeeding or females of childbearing potential with no adequate
             contraceptive precautions, other than oral contraceptives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa M Antonijoan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d'Investigació de Medicaments Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigació de Medicaments Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metformin glycinate</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

